IL22 Cancer Research Results

IL22, Interleukin-22: Click to Expand ⟱
Source:
Type:
IL-22 has also been identified as a cancer-promoting cytokine since deregulation of the IL-22-IL-22R1 system is linked to different cancer entities including lung, breast, gastric, pancreatic and colon cancers.

IL-22 is often expressed in various cancers, including colorectal cancer, breast cancer, liver cancer, and lung cancer. Its expression can vary depending on the tumor type and the immune context. Elevated levels of IL-22 are frequently associated with the presence of tumor-infiltrating immune cells and can be produced by both immune and tumor cells.


Scientific Papers found: Click to Expand⟱
5704- BRU,    Brusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
- in-vivo, PSA, HaCaT
*Inflam↓, brusatol exhibits remarkable anti-inflammatory efficacy in murine models with ulcerative colitis, significantly diminishing serum levels of pro-inflammatory cytokines (e.g., IL-17 and TNF-α), inhibiting IL-22/STAT3 pathway activation,
*IL17↓,
*TNF-α↓,
*IL22↓,
*STAT3↓,
*other↝, brusatol holds promising therapeutic potential in regulating psoriasis with dyslipidemia.
*eff↑, Brusatol significantly reverses the protein profile in IMQ-induced psoriasiform skin lesions
*Dose?, treatment group (Bru) administered brusatol (9.2 mg/kg) via oral gavage for seven consecutive days.

3268- Lyco,    Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders
- Review, AD, NA
*BioAv↓, Lycopene bioavailability can be decreased by ageing, and some of the pathological states, such as cardiovascular diseases (CVDs)
*AntiCan↑, For instance, it has been shown that a higher dietary intake and circulating concentration of lycopene have protective effects against prostate cancer (PCa), in a dose-dependent way
*ROCK1↓, It remarkably lessened the expression of ROCK1, Ki-67, ICAM-1 and ROCK2,
*Ki-67↓,
*ICAM-1↓,
*cardioP↑, Lycopene is a cardioprotective nutraceutical.
*antiOx↑, Lycopene is a well-known antioxidant.
*NQO1↑, Furthermore, lycopene supplementation improves mRNA expressions of the NQO-1 and HO-1 as antioxidant enzymes.
*HO-1↑,
*TNF-α↓, downregulate inflammatory cytokines (i.e., TNF-α, and IL-1β) in the hippocampus of the mice.
*IL22↓,
*NRF2↑, Lycopene decreased neuronal oxidative damage by activating Nrf2, as well as by inactivating NF-κB translocation in H2O2-related SH-SY5Y cell model
*NF-kB↓,
*MDA↓, significantly reduced the malondialdehyde (MDA)
*Catalase↑, Furthermore, it improved the catalase (CAT), superoxide dismutase (SOD), and GSH levels, and antioxidant capacity [109].
*SOD↑,
*GSH↑,
*cognitive↑, Lycopene administration considerably improved cognitive defects, noticeably reduced MDA levels and elevated GSH-Px activity, and remarkably reduced tau
*tau↓,
*hepatoP↑, Lycopene was also found to be effective against hepatotoxicity by acting as an antioxidant, regulating total glutathione (tGSH) and CAT concentrations
*MMP2↑, It also elevated MMP-2 down-regulation
*AST↓, lowering the liver enzymes levels, like aspartate transaminase (AST), alanine transaminase (ALT), LDL, free fatty acid, and MDA.
*ALAT↓,
*P450↑, Moreover, tomato powder has been shown to have a protective agent against alcohol-induced hepatic injury by inducing cytochrome p450 2E1
*DNAdam↓, lycopene decreased DNA damage
*ROS↓, It has been revealed that they inhibited ROS production, protected antioxidant enzymes, and reversed hepatotoxicity in rats’ liver
*neuroP↑, lycopene consumption relieved cognitive defects, age-related memory loss, neuronal damage, and synaptic dysfunction of the brain.
*memory↑,
*Ca+2↓, Lycopene suppressed the 4-AP-invoked release of glutamate and elevated intra-synaptosomal Ca2+ level.
*Dose↝, an in vivo study revealed that lycopene (6.5 mg/day) was effective against cancer in men [147]. However, lycopene dose should be increased up to 10 mg/day, in the case of advanced PCa.
*Dose↑, lycopene supplementation (15 mg/day, for 12 weeks) in an old aged population improved immune function through increasing natural killer cell activity by 28%
*Dose↝, Finally, according to different epidemiological studies, daily lycopene intake can be suggested to be 2 to 20 mg per day
*toxicity∅, A toxicological study on rats showed the no-observed-adverse-effect level at the highest examined dose (i.e., 1.0% in the diet)
PGE2↓, Lycopene doses of 0, 10, 20, and 30 µM were used to treat human colorectal cancer cell. Prostaglandin E2 (PGE2), and NO levels declined after lycopene administration,
CDK2↓, Treatment with lycopene reduced cell hyperproliferation induced by UVB and ultimately promoted apoptosis and reduced CDK2 and CDK4 complex in SKH-1 hairless mice
CDK4↓,
STAT3↓, lycopene reduced the STAT3 expression in ovarian tissues
NOX↓, (SK-Hep-1) cells and indicated a substantial reduction in NOX activity. Moreover, it inhibits the protein expression of NOX4, NOX4 mRNA and ROS intracellular amounts
NOX4↓,
ROS↓,
*SREBP1↓, Lycopene decreases the fatty acid synthase (FAS), sterol regulatory element-binding protein 1c (SREBP-1c), and Acetyl-CoA carboxylase (ACC1) expression in HFD mice.
*FASN↓,
*ACC↓,

193- MFrot,  MF,    Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions
- in-vivo, Arthritis, NA
BMD↑, loss reduced
Cartilage↑, more intact cartilage surfaces and denser proteoglycan
IL17↓,
IL22↓,
IL23↓,
IL28↓,
CD4+↓, tremendously attenuated
CD8+↓, In this investigation, data showed that RMF treatment decreased CD3-expressing proliferative cells via immunostaining and reduced CD4+/CD8+ T-cells via flow cytometry in AS mice
LAMB3↑,
COL4↓,
THBS2↓,
ITGA11↓,
PPARγ↑, mice have decreased expression of peroxisome proliferator-activated receptor γ (PPAR-γ), a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily, which RMF reverses.
ACAA1↓,
PLIN1↓,
FABP4↓,
PCK1↓,
UCP1↓,
TNF-α↓,

1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, In this study, we demonstrated that piperlongumine (PPL) treatment effectively abrogated the hyperproliferation and differentiation of keratinocytes by inducing ROS-mediated late apoptosis with loss of mitochondrial membrane potential.
Apoptosis↑,
MMP↓,
TumCCA↑, the arrest of cell cycle was found at Sub-G1 phase as a result of DNA fragmentation.
DNAdam↑,
STAT3↓, inhibition of STAT3 and Akt signaling was observed
Akt↓,
PCNA↓, decrease in proliferative markers such as PCNA, ki67, and Cyclin D1 along with anti-apoptotic Bcl-2 protein expression
Ki-67↓,
cycD1/CCND1↓,
Bcl-2↓,
K17↓, Keratin 17 is a critical regulator of keratinocyte differentiation, and it was found to be downregulated with PPL significantly
HDAC↓, PPL epigenetically inhibited histone-modifying enzymes, which include histone deacetylases (HDACs) of class I (HDAC1–4) and class II (HDAC6)
ROS↑, PPL at 5 and 10 µM concentration increased the reactive oxygen species (ROS) levels and a marked increase in oxidative stress were observed when combined with H2O2
*IL1β↓, Topical IMQ prominently induced the levels of pro-inflammatory cytokines, including IL-1β, IL-6, TNF-α, IL-17, IL-22, and transforming growth factor (TGF)-β, while PPL significantly suppressed these levels
*IL6↓,
*TNF-α↓,
*IL17↓,
*IL22↓,

5624- ProBio,  Bif,    A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
- Trial, Testi, NA
Dose↝, 07 mg of Lactobacillus acidophilus BCMC® 12,130, Lactobacillus lactis BCMC® 12,451, Lactobacillus casei subsp BCMC® 12,313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis
TNF-α↓, Significant reduction in the level of pro-inflammatory cytokine, TNF-α, IL-6, IL-10, IL-12, IL-17A, IL-17C and IL-22 were observed in CRC patients who received probiotics as compared to pre-treatment level (P < 0.05).
IL6↓,
IL10↓,
IL12↓,
IL22↓,
toxicity↓, We have shown that probiotics containing six viable microorganisms of Lactobacillus and Bifidobacteria strains are safe to be consumed at four weeks after surgery in colorectal cancer patients and have reduced pro-inflammatory cytokines (except for I


Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

NOX4↓, 1,   ROS↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics

MMP↓, 1,   UCP1↓, 1,  

Core Metabolism/Glycolysis

ACAA1↓, 1,   FABP4↓, 1,   PCK1↓, 1,   PLIN1↓, 1,   PPARγ↑, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 1,  

DNA Damage & Repair

DNAdam↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

HDAC↓, 1,   STAT3↓, 2,  

Migration

Cartilage↑, 1,   COL4↓, 1,   ITGA11↓, 1,   Ki-67↓, 1,   LAMB3↑, 1,   THBS2↓, 1,  

Immune & Inflammatory Signaling

CD4+↓, 1,   IL10↓, 1,   IL12↓, 1,   IL17↓, 1,   IL22↓, 2,   IL23↓, 1,   IL28↓, 1,   IL6↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment

NOX↓, 1,  

Drug Metabolism & Resistance

Dose↝, 1,  

Clinical Biomarkers

BMD↑, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes

K17↓, 1,   toxicity↓, 1,  

Infection & Microbiome

CD8+↓, 1,  
Total Targets: 45

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 1,   HO-1↑, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis

ACC↓, 1,   ALAT↓, 1,   FASN↓, 1,   SREBP1↓, 1,  

Transcription & Epigenetics

other↝, 1,  

DNA Damage & Repair

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State

STAT3↓, 1,  

Migration

Ca+2↓, 1,   Ki-67↓, 1,   MMP2↑, 1,   ROCK1↓, 1,  

Immune & Inflammatory Signaling

ICAM-1↓, 1,   IL17↓, 2,   IL1β↓, 1,   IL22↓, 3,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission

tau↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   Dose?, 1,   Dose↑, 1,   Dose↝, 2,   eff↑, 1,   P450↑, 1,  

Clinical Biomarkers

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes

AntiCan↑, 1,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   toxicity∅, 1,  
Total Targets: 46

Scientific Paper Hit Count for: IL22, Interleukin-22
1 brusatol
1 Lycopene
1 Magnetic Field Rotating
1 Magnetic Fields
1 Piperlongumine
1 probiotics
1 Bifidobacterium
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:541  State#:%  Dir#:1
wNotes=on sortOrder:rid,rpid

 

Home Page